Research programme: anti-interleukin monoclonal antibodies - OREGA Biotech

Drug Profile

Research programme: anti-interleukin monoclonal antibodies - OREGA Biotech

Alternative Names: Anti-IL-17B mAbs; IL-17B neutralising antibodies

Latest Information Update: 15 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orega Biotech
  • Developer INSERM; Institut Godinots; OREGA Biotech
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Interleukin-17 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 18 Apr 2017 OREGA Biotech has patent pending for anti-IL-17 antibodies in USA
  • 01 Apr 2017 Preclinical trials in Inflammation in France (Parenteral) before April 2017
  • 31 Dec 2016 OREGA Biotech has patent protection for anti-IL-17 antibodies in Europe before December 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top